Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Post neoadjuvant management in BRCA mutant breast cancer patients

BGICC 2023

19 - 20 Jan 2023

Published: 31 Jan 2023

Views: 17

Rating:

Save

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Prof Banu Arun speaks to ecancer as part of BGICC 2023 about post neoadjuvant management in BRCA mutant breast cancer patients.

She summarises the treatment options for patients with germline BRCA mutations who received neoadjuvant chemotherapy.

Some of these treatment options include pembrolizumab and olaparib.

Related Videos

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

More from ecancer